Table 7.
Summary of subgroup analysis, showing drugs having significant protective association in one subgroup but significantly different OR in the other subgroup (FDR < 0.2).
| Subgp | Windows | Model | OR_Y | OR_N | sig_Y | sig_N | z_OR_cmp | p_OR_cmp | p.adjust_OR_cmp | Name |
|---|---|---|---|---|---|---|---|---|---|---|
| AGE > 70 | 5 years | F | 0.81 | 0.99 | 1 | 0 | −2.65 | 8.15 × 10−3 | 1.47 × 10−1 | A02BC Proton pump inhibitors |
| AGE > 70 | 1 year | E | 1.19 | 0.49 | 0 | 1 | 2.11 | 3.47 × 10−2 | 1.56 × 10−1 | A10AE Insulins and analogues for injection, long-acting |
| AGE > 70 | 1 year | E | 0.81 | 1.04 | 1 | 0 | −2.38 | 1.72 × 10−2 | 1.55 × 10−1 | C09AA ACE inhibitors, plain |
| Asthma | 5 years | E | 0.60 | 0.86 | 1 | 1 | −2.66 | 7.76 × 10−3 | 1.40 × 10−1 | J07BB Influenza vaccines |
| Asthma | 10 years | E | 0.61 | 0.87 | 1 | 1 | −2.95 | 3.22 × 10−3 | 1.29 × 10−2 | J07BB Influenza vaccines |
| BMI > 30 | 1 year | F | 1.04 | 0.31 | 0 | 1 | 2.42 | 1.56 × 10−2 | 1.40 × 10−1 | J07AL Pneumococcal vaccines |
| BMI > 30 | 1 year | F | 0.76 | 0.54 | 1 | 1 | 2.52 | 1.17 × 10−2 | 1.40 × 10−1 | J07BB Influenza vaccines |
| BMI > 30 | 2 years | F | 0.79 | 0.56 | 1 | 1 | 2.75 | 6.01 × 10−3 | 1.08 × 10−1 | J07BB Influenza vaccines |
| BMI > 30 | 6 months | F | 0.92 | 0.16 | 0 | 1 | 2.68 | 7.40 × 10−3 | 1.26 × 10−1 | R03BA Glucocorticoids |
| CAD | 5 years | H | 0.36 | 1.32 | 1 | 0 | −2.39 | 1.71 × 10−2 | 1.53 × 10−1 | C08CA Dihydropyridine derivatives |
| CAD | 5 years | H | 1.72 | 0.18 | 0 | 1 | 2.42 | 1.53 × 10−2 | 1.53 × 10−1 | G04CB Testosterone-5-alpha reductase inhibitors |
| CAD | 5 years | C | 1.92 | 0.56 | 0 | 1 | 2.38 | 1.72 × 10−2 | 1.55 × 10−1 | J07AL Pneumococcal vaccines |
| CAD | 5 years | F | 1.55 | 0.56 | 0 | 1 | 2.55 | 1.07 × 10−2 | 1.92 × 10−1 | J07AL Pneumococcal vaccines |
| Depression | 1 yearr | B | 0.07 | 0.73 | 1 | 0 | −2.60 | 9.36 × 10−3 | 1.50 × 10−1 | C10AA HMG CoA reductase inhibitors |
| HT | 2 years | F | 0.75 | 0.93 | 1 | 0 | −2.69 | 7.20 × 10−3 | 1.30 × 10−1 | A02BC Proton pump inhibitors |
| HT | 5 years | F | 0.76 | 1.00 | 1 | 0 | −3.36 | 7.92 × 10−4 | 1.43 × 10−2 | A02BC Proton pump inhibitors |
| HT | 1 year | E | 0.86 | 1.07 | 1 | 0 | −2.11 | 3.49 × 10−2 | 1.26 × 10−1 | C09AA ACE inhibitors, plain |
| HT | 1 year | C | 0.71 | 1.02 | 1 | 0 | −2.58 | 9.90 × 10−3 | 8.91 × 10−2 | C10AA HMG CoA reductase inhibitors |
OR_Y, odds ratio within the subgroup defined in the 1st column; OR_N, OR in the other subgroup. Sig_Y, sig_N, significance in the two subgroups, 1 denotes significant protective effect, 0 denotes nonsignificant effect, −1 denotes significant harmful effect. p_OR_cmp, p-value based on comparison of ORs; p.adjust_OR_cmp, corresponding FDR. Ethnicity as a subgroup is not shown here; please refer to Table S11 for details. CAD, coronary artery disease, HT, hypertension.